Licensed vaccine
NUVAXOVID
FDA-licensed vaccine · Novavax, Inc. · STN 125817
Key facts
| Trade name | NUVAXOVID |
|---|---|
| Proper name | COVID-19 Vaccine, Adjuvanted |
| Manufacturer | Novavax, Inc. |
| Submission tracking number (STN) | 125817 |
| FDA product areas | Biologics, Vaccines |
| Recent FDA documents | May 16, 2025 Approval Letter - NUVAXOVID, Package Insert - NUVAXOVID |
| FDA page updated | May 17, 2025 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 1–9 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: